JCR Pharmaceuticals Co (TSE:4552) EBIT : 円7,531 Mil (TTM As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is JCR Pharmaceuticals Co EBIT?

JCR Pharmaceuticals Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was 円274 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was 円7,531 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. JCR Pharmaceuticals Co's annualized ROC % for the quarter that ended in Dec. 2023 was -1.55%. JCR Pharmaceuticals Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 2.23%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. JCR Pharmaceuticals Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 9.94%.

JCR Pharmaceuticals Co EBIT Historical Data

The historical data trend for JCR Pharmaceuticals Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JCR Pharmaceuticals Co EBIT Chart

JCR Pharmaceuticals Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EBIT

Get a 7-Day Free Trial

3,444.00

8,695.00

19,449.00

5,456.00

7,531.00

JCR Pharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															143.00	2,279.00	4,881.00	274.00	97.00

Competitive Comparison of JCR Pharmaceuticals Co's EBIT

For the Drug Manufacturers - General subindustry, JCR Pharmaceuticals Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

JCR Pharmaceuticals Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, JCR Pharmaceuticals Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where JCR Pharmaceuticals Co's EV-to-EBIT falls into.

JCR Pharmaceuticals Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円7,531 Mil.

JCR Pharmaceuticals Co (TSE:4552) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

JCR Pharmaceuticals Co's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	3644 * ( 1 - 135.06% )	/	( (84363	+	80955)	/ 2 )
=	-1277.5864	/	82659
=	-1.55 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	103988	-	3657	-	( 15968	-	max(0, 31995	-	57898	+	15968	))
=	84363

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	102773	-	3517	-	( 18301	-	max(0, 31914	-	57468	+	18301	))
=	80955

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

JCR Pharmaceuticals Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	1096	/	( ( (30964 + max(19635, 0))	+	(30657 + max(16953, 0)) )	/	2 )
=	1096	/	( ( 50599	+	47610 )	/	2 )
=	1096	/	49104.5
=	2.23 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(20514	+	19272	+	2144)	-	(3657	+	0	+	18638)
=	19635

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(16280	+	20830	+	2057)	-	(3517	+	0	+	18697)
=	16953

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

JCR Pharmaceuticals Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	7531	/	75763.091
	=	9.94 %

JCR Pharmaceuticals Co EBIT Related Terms

Thank you for viewing the detailed overview of JCR Pharmaceuticals Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

JCR Pharmaceuticals Co (TSE:4552) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » JCR Pharmaceuticals Co Ltd (TSE:4552) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

JCRRF:USA

Address

3-19 Kasuga-cho, Ashiya, Hyogo, JPN, 659-0021

Website

http://www.jcrpharm.co.jp

JCR Pharmaceuticals Co Ltd is a major drug manufacturing company proactively engaged in the research of enzymes and proteins. The company maintains a focus toward developing value-added treatment options to address unmet medical needs. JCR utilizes international partnerships as a component of its growth strategy. The vast majority of JCR's revenue is generated from its pharmaceutical operations, followed by medical devices and laboratory equipment. A portion of the company's sales are derived from licensing agreements.

JCR Pharmaceuticals Co (TSE:4552) Headlines

No Headlines